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Abstract 22 
 23 
Background: Fatigue has a major influence on the quality of life of people with multiple 24 
sclerosis. The Fatigue Severity Scale is a frequently used patient-reported measure of 25 
fatigue impact, but does not generate the health state utility values required to inform cost-26 
effectiveness analysis, limiting its applicability within decision-making contexts. The objective 27 
of this study was to use statistical mapping methods to convert Fatigue Severity Scale 28 
scores to health state utility values from three preference-based measures: the EQ-5D-3L, 29 
SF-6D and Multiple Sclerosis Impact Scale-8D.  30 
 31 
Methods: The relationships between the measures were estimated through regression 32 
analysis using cohort data from 1056 people with multiple sclerosis in South West England. 33 
Estimation errors were assessed and predictive performance of the best models were tested 34 
in a separate sample (n=352).  35 
 36 
Results: For the EQ-5D and the Multiple Sclerosis Impact Scale-8D, the best performing 37 
models used a censored least absolute deviation specification, with Fatigue Severity Scale 38 
total score, age and gender as predictors. For the SF-6D, the best performing model used 39 
an ordinary least squares specification, with Fatigue Severity Scale total score as the only 40 
predictor.  41 
 42 
Conclusions: Here we present algorithms to convert Fatigue Severity Scales scores into 43 
health state utility values based on three preference-based measures. These values may be 44 
used to estimate quality adjusted life-years for use in cost-effectiveness analyses and to 45 
consider the health-related quality of life of people with multiple sclerosis, thereby informing 46 
health policy decisions.  47 
 48 
 49 
50 
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Background 51 
 52 
Over the last two decades, various disease-modifying and symptomatic treatments have 53 
been developed for people with MS. Meanwhile, increasing emphasis has been placed on 54 
achieving “value for money” within healthcare systems (1). Clinical trials of interventions that 55 
target particular symptoms frequently use symptom-specific outcome measures in order to 56 
maximise sensitivity and responsiveness to change. Fatigue is the most common symptom 57 
experienced by people with MS, and has a considerable impact on quality of life (2).  The 58 
Fatigue Severity Scale (FSS) (3) is frequently used in clinical trials of interventions for fatigue 59 
in people with MS, including carnitine, amantadine, aspirin, modafinil and cognitive 60 
behavioural therapy (4) (5) (6) (7). Symptom-specific outcome measures, such as the FSS, 61 
provide a standardised means of describing “health states” that may be experienced by 62 
patients, but do not provide data in the format required by many decision-making bodies to 63 
assess cost-effectiveness (1).  64 
 65 
The quality-adjusted life-year (QALY) is recommended for use as an outcome measure for 66 
cost-effectiveness analyses by several national decision-making bodies, eg the National 67 
Institute for Health and Care Excellence (NICE) (8) (9) (10). QALYs combine quantity and 68 
quality of life in a single measure, by adjusting the number of life-years lived according to the 69 
quality-of-life experienced during those years (1). In order to estimate QALYs, numerical 70 
values must be assigned to reflect the quality of life experienced when living in particular 71 
health states. These values are commonly obtained using preference-based measures 72 
(PBMs) of health-related quality of life (11).  73 
 74 
However, many clinical trials do not include a PBM, limiting the ability to conduct economic 75 
evaluations. In such cases, statistical procedures may be used to “map” scores on non-76 
preference based outcome measures, such as the FSS, to HSUVs derived from PBMs. 77 
“Mapping’ involves regression analysis, using a dataset containing responses to both 78 
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measures from the same sample, to derive an algorithm that can be used to convert data 79 
from non-preference-based measures into HSUVs. Over recent years, the use of mapping 80 
has increased considerably (11). Previous studies have reported on mapping from MS-81 
specific outcome measures including the Multiple Sclerosis Impact Scale and the Multiple 82 
Sclerosis Walking Scale-12 (12) (13) (14). However, no approach has been reported that 83 
uses fatigue measures to map to HSUVs in the context of MS. 84 
 85 
 86 
Methods 87 
 88 
This paper uses statistical techniques to map from the FSS (the “source measure”) to 89 
HSUVs derived from three preference-based measures: the EQ-5D, SF-6D and MSIS-8D 90 
(the “target measures”). The aim is to derive algorithms to convert FSS scores into HSUVs 91 
for use in assessing the cost-effectiveness of treatments for fatigue in people with MS. The 92 
statistical approach presented here is based on good practice methodology, and is 93 
consistent with the recommendations regarding mapping methods from NICE in the UK (15) 94 
and the international ISPOR Good Practices for Outcomes Research Task Force (16). 95 
 96 
Measures 97 
 98 
The Fatigue Severity Scale (FSS) has acceptable reliability, internal consistency, sensitivity 99 
and responsiveness for people with MS (3) (17) (18) (19) (20) (21). It comprises nine 100 
statements, describing the severity and impact of fatigue, with a scale of possible responses 101 
ranging from 1 (“strongly disagree”) to 7 (“strongly agree”). FSS total scores are usually 102 
reported as the mean score over the nine items; a higher score indicates greater severity. 103 
 104 
The EuroQoL EQ-5D-3L has five dimensions (mobility, self-care, usual activities, 105 
pain/discomfort, anxiety/depression) with three response levels per dimension - no 106 
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problems, some problems or extreme problems/confined to bed. HSUVs were derived from 107 
the preferences of a representative sample of the UK general population, using a variant of 108 
the time trade-off (TTO) technique, and range from -0.594 to 1.000 (22). The EQ-5D is 109 
widely used in economic evaluation, particularly in the UK, where NICE recommend it as the 110 
preferred measure of health outcomes for cost effectiveness analyses (8).  111 
 112 
The Short-Form 6D (SF-6D) enables HSUVs to be estimated from a popular non-preference 113 
based measure of HRQoL, the Short-Form 36 (SF-36). It consists of six dimensions 114 
(physical functioning, role limitations, social functioning, pain, mental health, vitality) with 115 
between four and six response levels. Preferences were elicited from a representative 116 
sample of the UK general population using the standard gamble technique and values range 117 
from 0.301 to 1.000 (23). The SWIMS dataset includes responses to Version 1 of the SF-36 118 
from earlier waves of data collection, before this was replaced by SF-36 Version 2, which 119 
was developed to address concerns about the structure and wording of some items (24). 120 
Given that the component items of the SF-6D classification system differ between the two 121 
versions, we only included responses to Version 2 of the SF-36 in this analysis, in order to 122 
ensure consistency. 123 
 124 
The Multiple Sclerosis Impact Scale 8D (MSIS-8D) enables HSUVs to be estimated from 125 
responses to an MS-specific outcome measure, the Multiple Sclerosis Impact Scale (MSIS-126 
29). It includes eight dimensions (physical function; social and leisure activities, mobility, 127 
daily activities, mental fatigue, emotional well-being, cognition, depression) with four 128 
response levels (25). HSUVs were derived from a TTO survey with a sample of the UK 129 
general population. Values range from 0.079 to 0.882. It was not assumed that the best 130 
health state described by the MSIS-8D classification system (ie “no problems” on all 131 
dimensions) was equivalent to perfect health, therefore the value of this health state was not 132 
constrained to 1 (26). The MSIS-8D was derived from Version 2 of the MSIS-29 (21), which 133 
has four response levels per item, rather than Version 1 of the MSIS-29, which has five 134 
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response levels (27). Therefore, although earlier waves of SWIMS data collection used 135 
Version 1 of the MSIS-29, only responses to Version 2 were included in this analysis. 136 
 137 
 138 
Dataset 139 
 140 
The South West Impact of Multiple Sclerosis (SWIMS) project is a longitudinal cohort study 141 
of people with MS aged 18 or over, living in Devon and Cornwall. Respondents complete six-142 
monthly questionnaires, including several patient-reported outcome measures alongside 143 
clinical and demographic characteristics. The study was approved in the UK by the Cornwall 144 
and Plymouth and South Devon Research Ethics Committees, and written informed consent 145 
is obtained from all participants.  146 
 147 
This analysis used SWIMS data received between August 2004 and October 2012.  Only 148 
data collected at baseline were included, as this is the only point at which the FSS, EQ-5D, 149 
SF-36 and MSIS-29 are completed simultaneously. A random sample of 75% of the baseline 150 
data were used as the estimation dataset (n=1056), with the remaining 25% constituting the 151 
validation dataset (n=352) (28) (11). As Table 1 shows, there were no significant differences 152 
(p<0.05) between the datasets in terms of mean FSS total scores, mean HSUVs, or 153 
recorded demographic or clinical characteristics. The mapping algorithms were derived 154 
using data from respondents who provided answers to all questions required to produce both 155 
a FSS total score and a HSUV from the target PBM: 1023 respondents for the EQ-5D, 607 156 
for the SF-6D and 650 for the MSIS-8D (response numbers are lower for the SF-6D and the 157 
MSIS-8D as only version 2 of these questionnaires were included). All statistical analysis 158 
was undertaken in Stata 14. 159 
 160 
 161 
Preliminary assessment of measures 162 
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 163 
Two key conditions must be met for mapping: there should be conceptual overlap between 164 
the source and target measures, and the target measure should demonstrate discriminative 165 
validity with respect to the severity of the condition captured by the source measure (11) 166 
(29). To assess conceptual overlap, the FSS items and the dimensions of the PBMs were 167 
allocated to a multi-dimensional conceptual framework, which was developed for this study 168 
in order to provide a structure for comparing the content of the measures. The measurement 169 
concept underpinning the three PBMs is health-related quality of life (HRQL) (22) (23) (25). 170 
Therefore, the conceptual framework was structured around the commonly agreed key 171 
dimensions of HRQL, which comprise physical and mental domains alongside a third domain 172 
relating to social and role function and participation (30) (31) (32). The framework was 173 
constructed based on a systematic literature review of qualitative research into the impact of 174 
fatigue on people with MS (details of this review are included as Supplementary Material A).  175 
Pearson correlation coefficients were assessed between the total FSS score and HSUVs 176 
from each of the PBMs, while Spearman correlation coefficients were assessed between 177 
FSS total scores and individual dimension scores for each PBM, and between HSUVs and 178 
individual FSS item scores. Assuming that these instruments measure distinct but related 179 
concepts, we expected to find relationships of moderate strength, ie correlation coefficients 180 
between 0.3 and 0.6 (33). To assess the discriminative validity of the PBMs, respondents 181 
were categorised into fatigue severity groups: “mild/ no fatigue” (FSS total ≤ 35), “moderate 182 
fatigue” (36 ≤ FSS total ≤ 52) and “severe fatigue” (FSS total ≥ 53). The definition of “mild/ 183 
no fatigue” was based on the published cut-off point for the FSS (17). The ability of the 184 
PBMs to differentiate between the three groups was investigated using ANOVA and 185 
standardised effect sizes. Effect sizes can be assessed as small (0.20–0.49), moderate 186 
(0.50–0.79) or large (0.80 or over) (34).   187 
 188 
 189 
Development of mapping algorithms 190 
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 191 
Exploration of model specifications 192 
 193 
The relationships between the source and target measures were examined using statistical 194 
conventions reported in the mapping literature (29) (35). The distribution of scores on each 195 
of the measures was explored by the production of histograms and, the relationship between 196 
each of the PBMS and the FSS total score was investigated by production of scatterplots. 197 
Five regression models were estimated for each PBM. HSUVs were regressed on the: 198 
• Total FSS score for the FSS (Model A); 199 
• Total FSS score for the FSS and total FSS score squared (Model B); 200 
• Total FSS score, age and gender (Model C); 201 
• FSS item scores (Model D);  202 
• FSS item scores, age and gender (Model E). 203 
 204 
The majority of mapping studies estimate algorithms using ordinary least squares (OLS) 205 
models (35). However, OLS models can predict values outside the possible range for a 206 
PBM, and can lack predictive accuracy for extreme HSUVs. To address this, Tobit models 207 
were also considered, specifying an upper limit of 1 (29). OLS and Tobit models rely on an 208 
assumption of no heteroscedasticity. Where this assumption was violated according to 209 
White’s test for heteroscedasticity, the ‘vce(robust)’ option was used in conjunction with the 210 
‘regress’ command for the OLS analyses, and Censored Least Adjusted Deviation (CLAD) 211 
estimation methods (36) were used instead of Tobit models, employing the ‘clad’ command 212 
with a specified upper limit of 1. 213 
 214 
Predictive ability was assessed using the following estimation errors: mean absolute error 215 
(MAE), root mean squared error (RMSE) and the proportions of estimates that fell within 216 
0.05, 0.10 and 0.25 of the observed HSUV. MAE was selected as the primary criterion for 217 
selection of the preferred models (11). However, if coefficients had unexpected signs these 218 
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models were not selected. In instances where model MAEs were the same, the model with 219 
the best profile of estimates falling within 0.05, 0.10 and 0.25 of the observed HSUV was 220 
selected.  221 
 222 
Two researchers decided independently which models to would take forward for validation. 223 
Where discrepancies arose, these were resolved through discussion until consensus was 224 
reached. Demographic variables may not be included in the datasets from which HSUVs are 225 
to be estimated. Therefore, where the best performing models included demographic 226 
variables, the best performing model without demographic variables was also selected. 227 
 228 
 229 
Validation and model selection 230 
 231 
Estimation errors were assessed according to the severity of the health state. The selected 232 
models were applied to the validation dataset and their performance was assessed using the 233 
criteria outlined above. 234 
 235 
 236 
Results 237 
 238 
Preliminary assessment of measures 239 
The conceptual framework that was developed to assess conceptual overlap between the 240 
measures is illustrated in Figure 1. Most of the themes that had been identified in the original 241 
qualitative research studies fitted into the three domains of HRQoL that were defined a priori. 242 
There were two notable exceptions. Several of the themes described the experience of 243 
fatigue itself, rather than its effect on HRQoL. This experience was clearly of great 244 
importance to the people with MS who contributed to the original research, and underpinned 245 
the ways in which fatigue impacts upon HRQoL. Therefore, an additional domain was added: 246 
10 
 
“Descriptions of fatigue”. In terms of the links between themes, a clear relationship emerged 247 
between “functioning and participation” and “psychological well-being”. People with MS 248 
specifically identified negative effects on their psychological well-being that were caused by 249 
the impact of their fatigue on their functioning and participation. These stood alongside, but 250 
distinct from, the direct impact of fatigue on psychological well-being. Therefore, this became 251 
a domain in its own right. 252 
 253 
In terms of conceptual overlap, the FSS and all PBMs cover the three primary domains of 254 
the conceptual framework (Physical, Mental and Participation Effects) (Table 2). Coverage of 255 
Participation Effects is strong across all four measures. The FSS, SF-6D and MSIS-8D 256 
capture a wide range of Physical Effects, whereas the EQ-5D includes only specific 257 
dimensions for pain/discomfort and mobility. In terms of Mental Effects, the FSS includes 258 
one item relating to motivation, while the PBMs describe other specific symptoms eg 259 
depression or anxiety. Only the MSIS-8D includes cognitive effects. The MSIS-8D and SF-260 
6D include dimensions relating specifically to fatigue or vitality.  261 
 262 
Significant (p<0.0001) moderate correlations were evident between the FSS total score and 263 
HSUVs derived from the EQ-5D (r = -0.455) and the MSIS-8D (-0.590). There was a large 264 
significant correlation (p<0.0001) between the FSS total score and HSUVs derived from the 265 
SF-6D (-0.647). The FSS total score was significantly correlated with all individual 266 
dimensions of the PBMs, and HSUVs derived from each of the PBMs were significantly 267 
correlated with all individual items of the FSS (p<0.0001). Most correlations were moderate, 268 
as anticipated, and all had the expected negative sign, ie higher FSS scores are related to 269 
lower HSUVs (Table 3).  270 
 271 
28.4% of respondents with a valid FSS total score were in the “mild/ no fatigue” category, 272 
36.6% were in the “moderate fatigue” category and 35.0% were in the “severe fatigue” 273 
category. All PBMs discriminated significantly between fatigue severity groups (p<0.0001). 274 
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The SF-6D performed particularly well, with large standardised effect sizes (≥0.80). Overall, 275 
standardised effect sizes were higher for the MSIS-8D than for the EQ-5D (Table 4). 276 
 277 
As a result of the preliminary assessments, it was judged that conceptual overlap and 278 
discriminative validity were sufficient to proceed with the estimation of mapping models. 279 
Overall, the SF-6D and MSIS-8D provide a better fit with the FSS.  280 
 281 
 282 
Results of mapping analysis 283 
 284 
Exploration of model specifications 285 
In order to allow for heteroscedasticity, skewness and kurtosis identified in the data, we fitted 286 
robust OLS models and used a CLAD rather than a Tobit specification. (The distribution of 287 
scores on each of the measures, and the relationships between scores on the PBMs and the 288 
FSS total score is shown in the Supplementary Material B and C). Thirty models were 289 
considered, with Models A to E estimated for each PBM, using both OLS and CLAD 290 
specifications.   291 
 292 
There was little difference between the predictive ability of the models based on FSS total 293 
scores and individual FSS items. In all models, item FSS-08 had a significant coefficient with 294 
an unexpected sign, and a majority of the FSS items (ranging from five to seven of the nine 295 
items) were not significant predictors of HSUVs. Furthermore, data on individual FSS items 296 
may not be available in all potential applications of the mapping algorithms. Therefore 297 
selection was restricted to algorithms based on the FSS total score. 298 
 299 
EQ-5D: CLAD C had the lowest MAE and the highest proportion of individuals with small 300 
prediction errors. We also selected CLAD A, as the model which did not include 301 
demographic variables with the lowest MAE. 302 
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 303 
SF-6D: OLS B and CLAD B had coefficients with unexpected signs and were, therefore, not 304 
selected. We selected CLAD C as it had the next lowest MAE, and OLS A and CLAD A, as 305 
they did not include demographic variables.  306 
 307 
MSIS-8D: CLAD B and OLS B had the lowest MAEs, however these had unexpected signs 308 
for FSS total, and so were not selected. The model with the next lowest MAE and highest 309 
proportion of individuals with small predictions errors was CLAD C. As this model included 310 
demographic variables, we also selected the model with the next lowest MAE (0.117), CLAD 311 
A. 312 
 313 
Details of the selected models are presented in Table 5.  All model results are provided in 314 
Supplementary Material D. 315 
 316 
 317 
Validation and model selection 318 
 319 
The validation dataset was used to assess estimation errors for the selected models (Table 320 
6). Table 7 shows MAEs for ‘poor’ and ‘good’ health states by model. The models predicting 321 
HSUVs for the EQ-5D and MSIS-8D had larger MAEs for poorer health states, indicating that 322 
these models performed less well at estimating EQ-5D scores for those in poorer health 323 
states. The opposite was true for the SF-6D models, although the difference in MAEs here 324 
was less marked. (Please see Supplementary Materials E and F).  325 
 326 
 327 
Discussion 328 
 329 
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Here we describe and demonstrate a method for converting responses to the FSS, a 330 
frequently-used measure of fatigue severity, into HSUVs, which can be used to estimate 331 
QALYs for use in cost-effectiveness analyses, and hence to inform decision-making 332 
regarding the availability of treatments for MS-related fatigue. According to the Oxford Health 333 
Economics Research Centre’s Mapping Database, last updated in April 2019 (37), no 334 
previous published studies have attempted mapping from the FSS. In addition, we have 335 
found no previous studies which have investigated correlations between the FSS and the 336 
SF-6D or the FSS and the MSIS-8D, and just two which have explored the relationship 337 
between the FSS and the EQ-5D (38) (39). Rosa et al. (39) correlated FSS total scores with 338 
participants’ scores on the EQ-5D visual analogue scale, rather than with the EQ-5D HSUVs 339 
that are relevant for mapping, and Tremmas et al. (38) found no statistically significant 340 
correlation between the FSS and EQ-5D scores of people with lung cancer.  341 
 342 
The ability of the models selected in the current study to predict SF-6D and MSIS-8D values 343 
is in keeping with results reported in other mapping studies (35). There are currently no 344 
guidelines regarding acceptable limits for estimation errors (13), but MAEs ranging from 345 
0.0011 to 0.19 have been previously described (35). In the current study, the SF-6D MAEs 346 
of 0.078 and 0.077 and the MSIS-8D MAEs of 0.117 and 0.116, fall well within this range 347 
and, specifically in the context of MS, they are in keeping with the MAE of 0.058 reported by 348 
Hawton et al. (12) when the MSIS-29 was mapped to the SF-6D.  349 
 350 
Results for the EQ-5D algorithms were less convincing. The prediction errors of 0.175 and 351 
0.173 are towards the higher end of MAEs reported in previous mapping studies (35), and 352 
are also high in the context of MS mapping studies. Versteegh et al. (13) mapped from the 353 
version 1 of the MSIS-29 to the EQ-5D, with a resulting MAEs of 0.13 and 0.16, and Hawton 354 
and colleagues (12) mapped from version 2 of the same measures to the EQ-5D with a MAE 355 
of 0.147. In addition, when testing the external validity of the Versteegh et al. (13) algorithm, 356 
Ernstsson et al. (40) reported a MAE of 0.12. 357 
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 358 
Information is inevitably lost in the process of mapping, as the resulting algorithm will only 359 
reflect the areas of content that overlap between the starting and target measures. This 360 
information loss is accentuated when a domain-specific, condition-specific measure, such as 361 
the FSS, is mapped to a generic, multi-dimensional measure, such as the EQ-5D. Therefore, 362 
greater predictions errors might be anticipated when mapping from such a uni-dimensional 363 
scale as the FSS than when mapping from a multi-dimensional scale such as the MSIS-29 364 
(41). However, this does not appear to hold in the MS mapping literature to date, with 365 
Hawton et al. (14) reporting a MAE of 0.148 when they mapped from the MS Walking Scale-366 
12 (a mobility-specific, MS-specific measure) to the EQ-5D, and Sidovar et al. (42) described 367 
an error statistic of 0.109 when mapping to/from these same measures.  368 
 369 
In the current study, the EQ-5D algorithms were particularly problematic for HSUVs below 370 
0.65. They did not predict any values below 0.54 (assuming an age of 50 years and female 371 
gender for CLAD Model C), which is of particular concern for a measure with a minimum 372 
value of -0.594. 373 
 374 
On the basis of the statistical assessments reported here, the qualitative assessments of 375 
conceptual validity, and setting our findings in the context of other mapping studies in MS 376 
and mapping studies more generally, we suggest the use of the following algorithms for 377 
mapping from the FSS to HSUVs.  378 
SF-6D estimate = 0.897 - 0.006*FSS total score 379 
MSIS-8D estimate = 1.084 - 0.008*FSS total score – 0.001*age – 0.0024*gender [0 male, 1 380 
female] or age and gender are not available: 381 
MSIS-8D estimate = 0.985 – 0.007*FSS total score 382 
Based on these same assessments, we suggest the EQ-5D algorithms are far less likely to 383 
produce accurate or valid estimates of EQ-5D scores.  384 
 385 
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There are a number of potential limitations of this work. Firstly, the SWIMS data were 386 
collected prior to the development and use of the EQ-5D-5L and the mapping algorithms 387 
were based on the ‘older’ EQ-5D-3L. It may have been expected that the EQ-5D-5L would 388 
supersede the EQ-5D-3L as it was developed with five, rather than the original three, levels 389 
in an attempt to improve its responsiveness. However, the English HSUV set for the EQ-5D-390 
5L is not in common use, and if using the EQ-5D-5L descriptive system, the current ‘position 391 
statement’ of NICE is to use a cross-walk algorithm to provide HSUVs from the EQ-5D-3L 392 
value set. Secondly, the SF-6D value set is based on the use of standard gamble to elicit 393 
preferences for health states. This may result in higher HSUVs (than the EQ-5D), as 394 
respondents tend to be risk adverse. Thirdly, we did not explore the performance of some of 395 
the ‘newer’ mapping model specifications, such as limited dependent variable mixture 396 
models or beta-based regression, which may have better accounted for the bi-modal nature 397 
of the EQ-5D data. There is some empirical evidence in support of these models, but the 398 
ISPOR Task Force report (16) does not advocate any specific regression approach for 399 
mapping, recognising that the performance of different methods will vary dependent on a 400 
number of factors including the nature of the starting/target measures, the disease, and the 401 
patient population. The report suggests it is wise to use a model type for which there is 402 
existing evidence of good performance. In the context of MS, mapping algorithms which 403 
have used the same regression approaches that we have used here have been reported 404 
with MAEs of 0.058 (12), 0.13 and 0.16 (13), 0.147 (12), 0.12 (40), 0.148 (14) and 0.109 405 
(42). Brazier et al.’s (35) systematic review of mapping studies reported MAEs of 0.0011 to 406 
0.19. Therefore, the regression approaches in the current paper have a track record of use 407 
and acceptability in the context of MS. The MAEs reported here for the SF-6D and MSIS-8D 408 
are in keeping with those reported in these other mapping studies. The poor performance of 409 
the EQ-5D algorithms is likely to be a function of the limited conceptual overlap between the 410 
EQ-5D and the FSS. The limited shared conceptual content of these measures will not be 411 
altered by using a different form of regression analysis. Thirdly, algorithms to predict HSUVs 412 
from individual FSS items, rather than the total score, were not generated by this study. This 413 
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was, in part, due to an anomaly affecting item FSS-08 (Fatigue is among the most disabling 414 
of my symptoms). While the item correlated negatively (as expected) with HSUVs when 415 
considered in isolation, it had a positive coefficient when included as an independent 416 
variable in regression analysis. Further research would be required to understand the 417 
mechanisms behind this; in the meantime, it is not possible to determine whether this item is 418 
suitable for inclusion in a mapping algorithm. 419 
 420 
A particular strength of this study is the nature of the SWIMS dataset. It has provided 421 
comprehensive data on which to base the estimation and validation of these mapping 422 
algorithms. Importantly, the cohort is comparable with other UK-based samples of people 423 
with MS in terms of age, gender, relapse rates and duration of illness (43) (44) (45) (46) (8) 424 
(47), meaning the algorithms should apply generally to people with MS, rather than just to 425 
specific sub-groups. In addition, the work undertaken to explore the content overlap between 426 
the measures provided a form of ‘triangulation’ in assessing the appropriateness of the 427 
mapping algorithms. Drawing on good quality qualitative research findings regarding the 428 
impacts of fatigue on HRQoL and developing a conceptual framework, provided unique 429 
insights into why the measures did and did not map well.  430 
 431 
It is acknowledged that mapping methods are a second-best option to directly collected 432 
HSUVs for estimating QALYs (29) (48) (41). Use of mapping increases the uncertainty and 433 
error around estimates of HSUVs (29), and is particularly problematic when there is little 434 
content overlap or relationship between the measures being mapped to and from (41). 435 
However, when PBM data are not collected directly in a trial, empirically-evidenced mapping 436 
algorithms may be used. With the exception of the EQ-5D, the algorithms reported here can 437 
be used to support improvements in decision-making where primary PBM data are 438 
unavailable.  439 
 440 
Conclusions 441 
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 442 
We present statistical algorithms that allow data from the FSS, a fatigue-specific patient-443 
reported outcome measure, to be used in the estimation of QALYs, which are a suitable and 444 
policy-relevant measure for use in cost-effectiveness analyses. This will enable the results of 445 
studies using the FSS to inform decision-making in a health technology assessment context. 446 
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Table 1: Summary of respondent characteristics, comparison of estimation and validation datasets  
 All baseline data Estimation dataset Validation dataset Difference1 
 Mean SD Observations Mean SD Observations Mean SD Observations t statistic p value 
Measure            
   FSS 43.73 15.10 1054 43.44 15.16 787 44.60 14.91 267 -1.085  0.278 
   EQ-5D 0.596 0.295 1346 0.600 0.291 1005 0.584 0.309 341 0.831 0.406 
   SF-6D 0.646 0.130 632 0.650 0.135 473 0.636 0.113 159 1.141 0.254 
   MSIS-8D 0.646 0.185 690 0.647 0.190 523 0.641 0.172 167 0.412 0.681 
Characteristic            
   Age 50.67 11.68 1400 50.74 11.73 1048 50.45 11.54 352 0.402 0.688 
   Duration (years) 9.62 10.01 1347 9.61 10.00 1009 9.68 10.09 338 -0.113 0.910 
   EDSS score 4.30 2.31 289 4.32 2.34 218    4.22 2.24 71 0.324 0.746  
Percentage Observations Percentage Observations Percentage Observations chi2 statistic p value 
Gender         
   Female 73.86% 1040 74.62% 788 71.59% 252 1.256 0.262 
   Male 26.14% 368 25.38% 268 28.41% 100   
MS type         
   Relapsing remitting 41.97% 572 42.66% 439 39.82% 133 7.572 0.109 
   Primary progressive 19.37% 264 18.56% 191 21.86% 73   
   Secondary progressive 16.95% 231 17.69% 182 14.67% 49   
   Benign 3.3% 45 3.69% 38 2.10% 7   
   DK or combination 18.42% 251 17.40% 179 21.56% 72   
   Missing  45  27  18   
Recent relapse2         
   Yes 53.55% 732 53.42% 546 53.91% 186 0.025 0.988 
   No 33.28% 455 33.37% 341 33.04% 114   
   Don’t know 13.17% 180 13.21% 135 13.04% 45   
   Missing  41  34  7   
SD = standard deviation; FSS = Fatigue Severity Scale; EQ-5D = EuroQoL EQ-5D-3L; SF-6D = Short-Form 6D; MSIS-8D = Multiple Sclerosis Impact Scale – Eight Dimensions; 
EDSS = Expanded Disability Status Scale; DK = don’t know. 
1Difference between estimation and validation datasets 
2relapse in the 12 months prior to completing the baseline questionnaire 
nb response numbers are lower for the SF-6D and the MSIS-8D as only version 2 of these questionnaires were included 
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Table 2: Comparison of measures against conceptual framework 
Conceptual framework Fatigue severity scale EQ-5D SF-6D MSIS-8D 
Descriptions of fatigue     
 General fatigue or vitality 3. Easily fatigued 
5. Causes frequent problems 
8. Among most disabling symptoms 
- 6. Vitality - 
Physical effects     
 General  4. Interferes with physical functioning 
6. Prevents sustained physical functioning 
- 1. Physical functioning 
 
1. Physically demanding tasks 
 Triggers  - - - 
 Specific physical effects 2. Exercise brings on fatigue 4. Pain/Discomfort 
1. Mobility 
4. Pain 3. Being stuck at home 
Mental effects     
 General - - - 5. Feeling mentally fatigued 
 Specific psychological effects 1. Motivation is lower 5. Anxiety/Depression 5. Mental health 6. Irritable, impatient, short-tempered 
8. Feeling depressed 
 Specific cognitive effects - - - 7. Problems concentrating 
 Indirect effects - - - - 
Participation effects     
 General  7. Interferes with duties & responsibilities 
9. Interferes with work, family, social life 
 - 3. Being stuck at home 
 
 Effects on specific activities  2. Self-Care 
3. Usual Activities 
1. Physical functioning 
2. Role limitations 
3. Social functioning  
4. Pain 
2. Social and leisure activities 
4. Work or other daily activities 
EQ-5D = EuroQoL EQ-5D-3L; SF-6D = Short-Form 6D; MSIS-8D = Multiple Sclerosis Impact Scale – Eight Dimensions 
Explanation for allocation of particular items: 
• SF-6D Physical functioning: included under both “Physical effects” and “Functioning/ participation” because level descriptions include “moderate/ vigorous activities” 
and “bathing and dressing” 
• SF-6D Pain: included under both “Physical effects” and “Functioning/ participation”  because level descriptions include “pain that interferes with your normal work” 
• SF-6D Mental health: included under “Specific psychological effects” because level descriptions refer to feeling “tense or downhearted and low” 
• SF-6D Role limitations: included under “Functioning/ participation – activities” because level descriptions refer to “work or other regular daily activities”. 
• MSIS-8D Being stuck at home: included under “Specific physical effects” because the MSIS-8D uses this question as a proxy for mobility, however we have also 
included it here under “Functioning/ participation” 
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Table 3: Correlations between Fatigue Severity Scale and preference-based measures 
FSS total score and PBM dimensions rho Observations 
EQ-5D versus FSS total score   
Mobility 0.423 1035 
Self-care 0.385 1048 
Usual activities 0.524 1051 
Pain/Discomfort 0.361 1047 
Anxiety/Depression 0.292 1049 
SF-6D versus FSS total score   
Physical functioning 0.547 649 
Role limitations 0.424 645 
Social functioning 0.530 644 
Pain 0.429 642 
Mental health 0.324 648 
Vitality 0.615 654 
MSIS-8D versus FSS total score   
Physically demanding tasks 0.585 656 
Social and leisure activities 0.560 652 
Mobility (being stuck at home) 0.489 656 
Work or other daily activities 0.558 655 
Feeling mentally fatigued 0.582 656 
Feeling irritable, impatient or short-tempered 0.377 654 
Problems concentrating 0.450 654 
Feeling depressed 0.320 653 
EQ-5D versus FSS item   
1 My motivation is lower -0.285 1040 
2 Exercise brings on my fatigue -0.382 1038 
3 I am easily fatigued -0.464 1040 
4 Interferes with physical functioning -0.471 1033 
5 Causes frequent problems for me -0.498 1039 
6 Prevents sustained physical functioning -0.527 1040 
7 interferes with duties and responsibilities -0.536 1038 
8 Among my most disabling symptoms -0.336 1035 
9 Interferes with work, family or social life -0.482 1039 
SF-6D versus FSS item   
1 My motivation is lower -0.400 614 
2 Exercise brings on my fatigue -0.409 614 
3 I am easily fatigued -0.545 614 
4 Interferes with physical functioning -0.541 612 
5 Causes frequent problems for me -0.585 614 
6 Prevents sustained physical functioning -0.575 614 
7 interferes with duties and responsibilities -0.623 613 
8 Among my most disabling symptoms -0.455 610 
9 Interferes with work, family or social life -0.603 614 
MSIS-8D versus FSS item   
1 My motivation is lower -0.387 659 
2 Exercise brings on my fatigue -0.423 659 
3 I am easily fatigued -0.560 659 
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4 Interferes with physical functioning -0.554 656 
5 Causes frequent problems for me -0.615 659 
6 Prevents sustained physical functioning -0.606 660 
7 interferes with duties and responsibilities -0.637 660 
8 Among my most disabling symptoms -0.428 656 
9 Interferes with work, family or social life -0.596 659 
All coefficients significant at p<0.0001 
PBM = preference-based measure; FSS = Fatigue Severity Scale; EQ-5D = 
EuroQoL EQ-5D-3L; SF-6D = Short-Form 6D; MSIS-8D = Multiple Sclerosis 
Impact Scale – Eight Dimensions 
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Table 4: Discriminative validity 
EQ-5D vs FSS groups Mean SD Obs SES 
Mild/no fatigue 0.775 0.218 297 0.615 
Moderate fatigue 0.641 0.233 369 0.803 
Severe fatigue 0.454 0.3 357 
 
FFS total 0.614 0.285 1,023 
 
F-statistic 131.84 Prob < 0.0001 
 
Bartlett's chi2 40.065 Prob < 0.0001 
 
SF-6D vs FSS groups 
    
Mild/no fatigue 0.747 0.124 189 0.871 
Moderate fatigue 0.639 0.099 225 0.879 
Severe fatigue 0.552 0.083 193 
 
FFS total 0.645 0.129 607 
 
F-statistic 172.46 Prob < 0.0001 
 
Bartlett's chi2 30.047 Prob < 0.0001 
 
MSIS-8D vs FSS groups 
    
Mild/no fatigue 0.764 0.115 202 0.739 
Moderate fatigue 0.679 0.134 240 1.381 
Severe fatigue 0.494 0.186 208 
 
FFS total 0.646 0.184 650 
 
F-statistic 180.71 Prob < 0.0001 
 
Bartlett chi2 51.434 Prob < 0.0001 
 
SD = standard deviation; obs = observations; SES = standardised 
effect size; FSS = Fatigue Severity Scale; EQ-5D = EuroQoL EQ-5D-
3L; SF-6D = Short-Form 6D; MSIS-8D = Multiple Sclerosis Impact 
Scale – Eight Dimensions 
 
  
28 
 
Table 5: Models mapping from FSS total to PBMs using estimation dataset 
 
 
EQ-5D SF-6D MSIS-8D  
CLAD A CLAD C OLS A CLAD A CLAD C CLAD A CLAD C  
Coeff SE Coeff SE Coeff SE Coeff SE Coeff SE Coeff SE Coeff SE 
FSS total -0.006* 0.0006 -0.006* 0.0006 -0.006* 0.0003 -0.006* 0.0004 -0.006* 0.0004 -0.007* 0.0007 -0.008* 0.0008 
Age 
  
-0.003* 0.0007 
    
-0.0005 0.0005 
  
-0.001 0.0008 
Female 
  
0.012 0.0133 
    
-0.012 0.0107 
  
-0.024 0.0233 
Constant 0.921 0.0256 1.058 0.0610 0.897 0.0151 0.913 0.0195 0.966 0.0374 0.985 0.0228 1.084 0.0719 
Observations 763 
 
755 
 
455 
 
455 
 
452 
 
474 
 
464 
 
F statistic 
    
357.45 
         
Prob>F 
    
<0.0001 
         
R-squared  
   
0.451 
         
Pseudo R2 0.107 
 
0.126 
   
0.267 
 
0.274 
 
0.196 
 
0.194 
 
Coefficients 1 
 
3 
 
1 
 
1 
 
3 
 
1 
 
3 
 
Significant coefficients 1 
 
2 
 
1 
 
1 
 
1 
 
1 
 
1 
 
Mean absolute error (MAE) 0.175 
 
0.173 
 
0.078 
 
0.078 
 
0.077 
 
0.117 
 
0.116 
 
Mean squared error (MSE) 0.066 
 
0.067 
 
0.01 
 
0.01 
 
0.01 
 
0.024 
 
0.023 
 
Root MSE 0.257 
 
0.258 
 
0.1 
 
0.1 
 
0.1 
 
0.154 
 
0.152 
 
Normalised root MSE 16.12% 
 
16.19% 
 
14.31% 
 
14.31% 
 
14.31% 
 
19.18% 
 
18.93% 
 
Individuals with MAE < 0.25 78.37% 
 
79.34% 
 
98.68% 
 
98.68% 
 
98.45% 
 
89.05% 
 
90.41% 
 
Individuals with MAE < 0.1 47.05% 
 
49.14% 
 
68.13% 
 
69.01% 
 
70.13% 
 
51.93% 
 
51.84% 
 
Individuals with MAE < 0.05 26.47% 
 
29.14% 
 
41.32% 
 
41.98% 
 
42.48% 
 
28.40% 
 
29.39% 
 
*p<0.001  
Coeff = model coefficient; SE = standard error; CLAD = Censored Least Adjusted Deviation model; EQ-5D = EuroQoL EQ-5D-3L; SF-6D = Short-Form 6D; MSIS-8D = Multiple 
Sclerosis Impact Scale – Eight Dimensions 
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Table 6: Models mapping from FSS total to PBMs using validation dataset 
 
 
EQ-5D SF-6D MSIS-8D 
 
CLAD A CLAD C OLS A CLAD A CLAD C CLAD A CLAD C 
 
Coeff SE Coeff SE Coeff SE Coeff SE Coeff SE Coeff SE Coeff SE 
FSS total -0.007* 0.0012 -0.008* 0.0011 -0.004* 0.0005 -0.004* 0.0007 -0.004* 0.0008 -0.006* 0.0010 -0.006* 0.0011 
Age 
  
-0.004* 0.0011 
    
0.0004 0.0009 
  
-0.001 0.0020 
Female 
  
-0.009 0.0260 
    
0.002 0.0187 
  
0.012 0.0395 
Constant 1.001 0.0549 1.233 0.0979 0.81 0.0261 0.793 0.0394 0.827 0.0781 0.939 0.0432 0.974 0.1252 
Observations 260 
 
258 
 
152 
 
152 
 
152 
 
157 
 
157 
 
F statistic 
    
54.71 
       
0.185 
 
Prob>F 
    
<0.0001 
         
R-squared 
    
0.316 
         
Pseudo R2 0.119 
 
0.141 
   
0.169 
 
0.169 
     
Coefficients 1 
 
3 
 
1 
 
1 
 
3 
 
1 
 
3 
 
Significant coefficients 1 
 
2 
 
1 
 
1 
 
1 
 
1 
 
1 
 
Mean absolute error (MAE) 0.183 
 
0.179 
 
0.068 
 
0.068 
 
0.071 
 
0.118 
 
0.114 
 
Mean squared error (MSE) 0.076 
 
0.071 
 
0.008 
 
0.008 
 
0.009 
 
0.023 
 
0.022 
 
Root MSE 0.276 
 
0.267 
 
0.09 
 
0.09 
 
0.095 
 
0.151 
 
0.149 
 
Normalised root MSE 17.31% 
 
16.75% 
 
12.88% 
 
12.88% 
 
13.59% 
 
18.80% 
 
18.56% 
 
Individuals with MAE < 0.25 78.85% 
 
76.92% 
 
98.68% 
 
98.03% 
 
98.03% 
 
92.36% 
 
91.08% 
 
Individuals with MAE < 0.1 49.62% 
 
47.31% 
 
76.32% 
 
75.00% 
 
75.66% 
 
50.32% 
 
52.23% 
 
Individuals with MAE < 0.05 24.62% 
 
25.77% 
 
48.68% 
 
46.05% 
 
46.05% 
 
22.93% 
 
31.21% 
 
*p<0.001  
Coeff = model coefficient; SE = standard error; CLAD = Censored Least Adjusted Deviation model; EQ-5D = EuroQoL EQ-5D-3L; SF-6D = Short-Form 6D; MSIS-8D = Multiple 
Sclerosis Impact Scale – Eight Dimensions 
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Table 7: Mean absolute errors by severity group 
FSS to EQ-5D CLAD Model A CLAD Model C OLS Model A 
EQ_5D<=0.65 0.234 0.238 
 
EQ_5D>0.65 0.123 0.115 
 
FSS to SF-6D 
   
SF_6D<=0.65 0.070 0.070 0.070 
SF_6D>0.65 0.088 0.088 0.088 
FSS to MSIS-8D 
   
MSIS_8D<=0.7 0.154 0.154 
 
MSIS_8D>0.7 0.082 0.082 
 
Cut-off points for EQ-5D, SF-6D and MSIS-8D were chosen to give 
roughly equally-sized groups. 
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Additional file 1 
 
Development of a conceptual framework describing the impact of fatigue on 
people with MS: a systematic review of the literature 
Aim: to identify the main impacts of fatigue on the quality of life of people with MS, from the 
perspective of people with MS. 
Objective: to review the qualitative literature on the impact of fatigue on the lived experiences of 
people with MS 
 
Methods 
Literature search methods 
A search design was developed based on three key components of the objective of the literature 
review: multiple sclerosis, fatigue and qualitative methods. 
MS search terms were based on those used for routine searches undertaken by the Cochrane 
Collaboration’s “Multiple sclerosis and rare diseases of the central nervous system” group [Cochrane 
2017].  
Fatigue search terms were based on those used in a review of interventions for fatigue in 
Parkinson’s disease undertaken by the Cochrane Movement Disorders Group [Elbers et al, 2014]. 
Qualitative search terms were based on those developed for the purposes of a study that 
investigated how to find qualitative research in the context of the medical literature [Shaw et al, 
2004]. 
Search terms within each component were combined using the Bayesian operator “or”. The 
components were combined using the “and” operator. 
Inclusion criteria 
• Original research using a qualitative methodology 
• Participants are people with MS, or include people with MS alongside people with other 
conditions, where the results for people with MS are separately identifiable 
• Papers with a stated aim of investigating the impact of fatigue on one or more aspects of 
(health-related) quality of life, well-being, functioning or participation 
• English language 
Exclusion criteria 
• Review papers 
• Papers that explore one or more aspects of (health-related) quality of life, well-being, 
functioning or participation in MS, without an a priori focus on fatigue. 
• Papers that focused on fatigue, but did not report on the impact of fatigue on (health-
related) quality of life, well-being, functioning or participation. 
32 
 
• Papers that did not present separately identifiable results for people with MS. 
 
 
Analysis methods 
The purpose of this review is to provide the background for mapping between the FSS and the EQ-
5D, SF-6D and MSIS-8D. The measurement concept underpinning the three selected PBMs is health-
related quality of life. Therefore, the results of the literature review were analysed using a 
conceptual framework based on the key dimensions of health-related quality of life.  
There is no firm agreement on which dimensions comprise HRQoL, however there is a consensus 
that, at a minimum, physical and psychological domains should be included [Riazi, 2006]. More 
recently, a third dimension, relating to social and role function and participation (ie one’s ability to 
perform ‘normal’ or expected activities and roles), has been added [Ware, 2003]. Therefore, the 
conceptual framework consisted of three broad domains: physical functioning, psychological and 
cognitive functioning, and social functioning and participation. 
The themes that were identified by the original analysis were extracted from the results sections of 
the papers and pasted into tables, including the name of the theme and a description of its contents. 
All identified themes were then allocated to the three domains of HRQoL. Any themes that were 
repeated across more than one study were combined and any links between themes were noted. 
Themes that did not fit into the HRQoL domains were collated separately. 
In the next stage, sub- domains were developed by grouping together themes that described similar 
concepts within each domains of HRQoL. The themes that did not fit into the HRQoL domains and 
the links between themes were explored to determine whether amendments needed to be made to 
the three-dimensional structure of the conceptual framework. This was then used to produce a 
conceptual framework of how fatigue affects the HRQoL of people with MS, for use in assessing the 
content validity of the source and target measures. 
 
Results 
Literature search results 
The literature search returned 1124 results. Based on the titles and abstracts of these, 1062 were 
excluded from further consideration. Of the remaining 62 studies, 11 were conference abstracts for 
which the full text was not available. The full text of the remaining 52 papers was obtained, and 
these were assessed against the inclusion and exclusion criteria. Seventeen papers were excluded 
because they focussed on aspects of fatigue other than its impact (n=7), they did not focus on 
fatigue (6), they did not use qualitative methods (3) or they were not primarily concerned with MS. 
Therefore, twelve papers remained for inclusion in the review. This is summarised in Figure A1. 
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Figure A1: Literature search results 
 
Development of the conceptual framework 
Most of the themes that had been identified in the original qualitative research studies fitted into 
the three domains of HRQoL that were defined a priori. There were two notable exceptions. Several 
of the themes described the experience of fatigue itself, rather than its effect on HRQoL. This 
experience was clearly of great important to the people with MS who contributed to the original 
research, and underpinned the ways in which fatigue impacts upon HRQoL. Therefore, an additional 
domain was added: “Descriptions of fatigue”. In terms of the links between themes, a clear 
relationship emerged between “functioning and participation” and “psychological well-being”. 
People with MS specifically identified negative effects on their psychological well-being that were 
caused by the impact of their fatigue on their functioning and participation. These stood alongside, 
but distinct from, the direct impact of fatigue on psychological well-being. Therefore, this became a 
domain in its own right.  
Tables A1 – A4 outline how the themes identified from the literature were mapped to the 
conceptual framework. The conceptual framework is illustrated in Figure A2.
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Table A1. Descriptions of fatigue 
1.1 Fatigue as a whole 
body experience 
Fatigue was experienced in the muscles, head, and entire body. It affects sensation in the whole body, from the hair to the toes. 
Fatigue was perceived in the body – whole of parts of the body were perceived differently than they were before. The body did not feel natural 
and could not be taken for granted; increased awareness of the body all the time. Strained body with diminished power. 
Two opposite perceptions of the body: (1) heavy & painful (2) numbed, dead, not quite awake, as if parts were missing. 
A feeling of having a heavy body; wanting to let their arms and hands hang down; impossible to raise the arms or hold the body up straight. 
Muscles feel too weak to support the body 
1.2 Betrayed by your 
own body 
Some felt betrayed when fatigue invaded the body. The body was hard to control and couldn’t be trusted. 
Body will not obey, eg try to lift leg and nothing happens. 
Their own bodies ruled them and they had to adjust themselves. Feeling feeble and unable to manage. 
1.3 All-consuming 
fatigue 
Participants experienced fatigue much of the time, and when they did not, they were thinking about it – always taking it into account.  
An ever-present, ongoing experience, unrelenting and virtually ever present, even after rest or sleep.  
A paralyzing force; although some small reserve of energy is still available, they feel virtually powerless to perform desired activities. 
Undertow Effect: suffocating fatigue characterized by energy impoverishment and absolute powerlessness, relieved only by sleep. 
Energy loss was very unpleasant, perceived as a form of paralyses and as an unstoppable destructive force invading the body, leaving 
participants unable to manage anything further. 
1.4 An unusual and 
invisible feeling 
A unique and novel sensation, an experience that is different from experiences of being tired when healthy 
Fatigue is invisible and difficult to describe 
1.5 Characteristics of 
the experience of 
fatigue 
Weariness, sleepiness, tired most days, weak at rest, exhausted after minimal activity 
Sudden, can happen very rapidly, unpredictable, uncontrollable 
Sensation of one’s batteries running out 
Need day rest or sleep 
Unrefreshing or broken nocturnal sleep 
1.6 Interactions with 
other symptoms 
Interaction of fatigue with other symptoms leads to difficulties 
Fatigue that worsens along with other symptoms 
Fatigue can exacerbate other MS symptoms and vice versa 
Individuals were affected differently by fatigue, and could experience fatigue in one or more different ways during the course of their MS. 
It was often hard to differentiate whether a participant was discussing fatigue or MS, as these terms seemed to be used interchangeably 
Many participants had experienced more than one state of fatigue during the course of their MS and, on occasion, one state of fatigue could trigger another. 
Rather than isolating fatigue, it’s more about the complex and unpredictable relationship between fatigue and other symptoms. 
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Table A2. Physical effects of fatigue 
2.1 Specific 
physical effects 
Difficulty walking 
Falling over 
Weakness/ muscle weakness 
Participants described different states of fatigue. 
Limbs heavy 
Speech problems 
Coordination 
Sensory disturbances/ visual disturbances 
Flickering and swimming or pounding sensation in their eyes, causing dizziness and nausea. 
Pain 
Balance. 
A temporary increase in physical symptoms was associated with increased fatigue. 
2.2 Physical 
triggers 
Physical exertion induces weakness/ worsens fatigue 
Fatigue due to unexpected actions 
The feeling of being fatigued increased because of the extra effort of arranging footsteps when walking.  
 
Table A3. Mental effects of fatigue 
3.1 Psychological 
effects of fatigue 
Emotional impact of fatigue 
A temporary increase in emotional symptoms was associated with increased fatigue. 
Participants described different states of fatigue including feelings of depression. 
Feelings of defeat 
3.2 Cognitive effects 
of fatigue 
General Cognitive impact of fatigue 
Participants described different states of fatigue including mental fogginess. 
Felt that their brain was not totally clear; felt like being struck in the head by a sledgehammer.  
Head experiences: “Brain-cheese,” a “hazy, out-of-body fatigue feeling,” and a “hangover.”  
Links to other symptoms, including cognition. 
A temporary increase in cognitive symptoms was associated with increased fatigue. 
Rather than isolating fatigue, it’s about the complex and unpredictable relationship between fatigue and cognition. 
Specific Difficulty concentrating or thinking clearly 
Perception of lower cognitive ability and energy 
Impact on daily life: difficulties in making decisions and plans 
Difficulty solving complex problems 
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Difficulty withstanding disturbing sounds 
Difficulties in remembering 
Making mistakes 
Only for brief moments could they feel totally focused. 
Not being able to look forward in time, thinking in the present moment. 
3.3 Psychological 
triggers of fatigue 
Cognitive Mental effort worsens fatigue 
Emotional Fatigue due to a change in mood 
Stress/anxiety worsens fatigue 
Vicious circle: thinking/ worrying about fatigue could cause fatigue, leaving them unable to complete the task 
3.4 Indirect 
psychological effects 
of fatigue  
 
(links to 
participation and 
functioning effects) 
Emotional 
impacts 
A feeling of having the will but not the ability: wanted to live life as before and be an active person. 
Anxiety 
Helpless and exposed.  
Insecurity 
Frustration, stress, sadness. 
Dissatisfaction 
Lower self-worth, despair, sorrow 
Shame; being misunderstood (eg being mistaken as being drunk).  
Anger 
Enjoyment 
of life 
Involuntary isolation 
Inability to enjoy social activities or hobbies 
No fun in life, feeling bored.  
Feeling trapped by having to live a very structured life; loss of spontaneity 
Prevention of a “normal” life due to fatigue 
Forced interruption of activities due to fatigue 
Inadequate satisfaction of one’s basic needs 
Identity Loss of sense of self due to fatigue 
Disappointment in a fatigued self 
Inability to tend to appearances due to fatigue 
Non-achievement of goals due to a gap in the expected and actual behavioral potential 
Loss of control, which appeared to threaten the self-integrity of the individual. 
Progressive losses including work, youth, driving, strength and energy, relationship roles; feeling “old before my time.”  
Losses of driver’s license and employment had emotional effects and challenged men’s self-identities within the family.  
Some felt they had progressively lost strength and energy, attributes they linked to “being a man.”  
Some described attributes associated with self-identity that either contributed to fatigue or helped them continue their exercise 
despite fatigue, ie stubbornness, determination. 
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 Those who were able to engage in valued activities—even if the intensity was less, or if they achieved them through a different route—
experienced positive feelings and a sense of control. Those who were unable to make goal adjustments disengaged from valued activities, 
resulting in negative feelings.  
 Ongoing frustration can lead to depression, particularly “when the frustrated goal is deeply connected to the core of the self”.  
 ‘The importance of having goals that were highly valued and related to activities and work prior to diagnosis allowed the men to feel a sense of 
achievement and optimism despite their losses.’ 
 
Table 4. Effects of fatigue on participation and functioning 
4.1 Pervasive impact Influences all activities and responsibilities at work, home, and play.  
Restrictions or interruptions to life, including changes in roles within the family, social life and working situation.  
Barriers to participation were not perceived to directly result from any single MS impairment eg fatigue or communication, but from a complex 
interplay between the impairments experienced by an individual, the coping strategies employed and people’s attitudes. 
4.2 Activities Put things off, force self to do things 
Unable to carry out daily tasks as could before  
Activities of daily living 
Housework 
Giving up work, working fewer hours 
Decreased opportunities for social interaction. 
Social activities/ hobbies 
4.3 Effects of 
strategies to manage 
fatigue 
Implications of having to plan ahead/ lead structured daily life/ build rest periods into daily routine = less opportunity for spontaneity 
Implications of having to reduce overall activity or prioritise certain activities over others = dilemmas over which things don’t get done 
Implications of having to take a planned or necessary cessation of physical activity 
Difficulty of employment due to the measures for treating fatigue, related to an interruption of activities 
May take up formal exercise, or other physical activities, in attempt to enhance resistance to fatigue  
Time-consuming: can’t hurry, need to take time and avoid stressful situations; doing things in advance, calmly and methodically. 
4.4 Roles and 
relationships 
Communication and 
fatigue 
Difficult for others to understand the person’s experiences and needs because fatigue is “invisible” and difficult to 
describe 
Fatigue increases the frequency and severity of communication symptoms, language-processing deficits, motor speech 
symptoms** 
Some communication symptoms occur only when experiencing fatigue - language processing difficulties and dysarthria** 
The interplay between fatigue and communication led to communication symptoms becoming more apparent to 
listeners. The resulting communication did not reflect how they would like to represent themselves (eg drunk or lazy 
rather than able and competent).** 
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Common to all participants was the enormous effort and pre-planning that remains hidden from communication 
partners, eg dealing with word finding and memory difficulties, keeping interactions operating as normally as possible on 
the surface.** 
Handling fatigue in 
relation to others 
Concealment, eg measures to limit activity without letting others know 
Measures to arrange an environment by gaining the support of others 
A feeling of being 
absent 
They felt as if they had been split in two parts: one part was participating while the other was just watching. 
Feeling both present and absent: seeing everything but feeling as if they weren’t there. Feeling anaesthetized; things just 
passing by. 
Unable to understand things happening around them or to participate in conversations due to lack of concentration. 
Letting people 
down/ causing 
problems 
Feeling unreliable and could not always keep promises. Leaving everything half-done due to unpredictable fatigue. 
Unable to participate in family activities; felt this was difficult for the rest of the family - the whole family was suffering.  
Problems in one’s life and friendships due to unpredictable fatigue 
Concern of causing friends trouble due to fatigue 
Dependency Perceptions of dependency - trapped in the sense of needing help from other people – involves feelings of being a 
burden 
4.5 Participation 
triggers 
Trying to accomplish too much 
Family, work or socioeconomic stress 
Continuous nature of burdens and actions 
Work 
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Figure A2: Conceptual framework of the impact of fatigue on people with MS 
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Additional file 2 
 
Histograms of source and target measures 
      
 
42 
 
      
 
43 
 
Additional file 3 
 
FSS total versus EQ-5D values 
 
 
FSS total versus SF-6D values 
 
 
FSS total versus MSIS-8D 
44 
 
 
  
45 
 
Additional file 4: All models run for this analysis 
Initial models run using estimation dataset 
OLS Model A: Regressing EQ-5D vs FSS total   
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  -0.008 0.001 -14.03 <0.0001 
       _cons  0.976 0.025 38.67 <0.0001 
R2 0.2007 
   
RMSE 0.25087 
   
Coefficients 1 
   
Sig coefficients 1 
   
 
Mean Std.Dev. Obs 
 
MAE 0.186 0.168 763 
 
MSE 0.063 0.113 
  
RMSE 0.251 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 577 75.62 
  
Individuals with MAE < 0.1 279 36.57 
  
Individuals with MAE < 0.05 150 19.66 
  
     
OLS Model B: Regressing EQ-5D vs FSS total and FSS total squared 
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  -0.002 0.003 -0.69 0.489 
 FSS_squared  0.000 0.000 -1.93 0.054 
       _cons  0.876 0.055 15.84 <0.0001 
R2 0.2046 
   
RMSE 0.25043 
   
Coefficients 2 
   
Sig coefficients 0 
   
 
Mean Std.Dev. Obs 
 
MAE 0.186 0.167 763 
 
MSE 0.062 0.112 
  
RMSE 0.250 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 578 75.75 
  
Individuals with MAE < 0.1 286 37.48 
  
Individuals with MAE < 0.05 155 20.31 
  
     
OLS Model C: Regressing EQ-5D vs FSS, age, gender 
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  -0.008 0.001 -13.86 <0.0001 
         age  -0.005 0.001 -6.39 <0.0001 
     female   -0.027 0.019 -1.37 0.170 
       _cons  1.235 0.043 28.43 <0.0001 
R2 0.2465 
   
RMSE 0.24499 
   
Coefficients 3 
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Sig coefficients 2 
   
 
Mean Std.Dev. Obs 
 
MAE 0.184 0.161 755 
 
MSE 0.060 0.103 
  
RMSE 0.244 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 567 75.10 
  
Individuals with MAE < 0.1 281 37.22 
  
Individuals with MAE < 0.05 138 18.28 
  
     
     
OLS Model D: Regressing EQ-5D vs FSS item scores 
EQ-5D Coefficient SE t P>|t| 
      FSS_01  0.012 0.007 1.84 0.066 
      FSS_02  -0.011 0.006 -1.87 0.062 
      FSS_03  -0.012 0.009 -1.32 0.186 
      FSS_04  -0.006 0.008 -0.68 0.499 
      FSS_05  -0.010 0.012 -0.84 0.401 
      FSS_06  -0.024 0.009 -2.73 0.007 
      FSS_07  -0.031 0.008 -3.96 <0.0001 
      FSS_08  0.031 0.006 4.73 <0.0001 
      FSS_09  -0.015 0.009 -1.75 0.081 
       _cons  0.901 0.032 28.44 <0.0001 
R2 0.2584 
   
RMSE 0.24292 
   
Coefficients 9 
   
Sig coefficients 3 
   
 
Mean Std.Dev. Obs 
 
MAE 0.182 0.159 763 
 
MSE 0.058 0.104 
  
RMSE 0.241 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 585 76.67 
  
Individuals with MAE < 0.1 287 37.61 
  
Individuals with MAE < 0.05 138 18.09 
  
     
OLS Model E: Regressing EQ-5D vs FSS item scores, age and gender  
EQ-5D Coefficient SE t P>|t| 
      FSS_01  0.011 0.006 1.77 0.076 
      FSS_02  -0.011 0.006 -1.79 0.074 
      FSS_03  -0.014 0.009 -1.66 0.097 
      FSS_04  -0.005 0.008 -0.64 0.521 
      FSS_05  -0.010 0.011 -0.84 0.402 
      FSS_06  -0.020 0.009 -2.24 0.025 
      FSS_07  -0.028 0.008 -3.63 <0.0001 
      FSS_08  0.030 0.006 4.70 <0.0001 
      FSS_09  -0.017 0.008 -2.08 0.038 
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         age  -0.004 0.001 -5.76 <0.0001 
     female   -0.039 0.019 -1.99 0.046 
       _cons  1.145 0.046 24.91 <0.0001 
R2 0.2953 
   
RMSE 0.23819 
   
Coefficients 11 
   
Sig coefficients 6 
   
 
Mean Std.Dev. Obs 
 
MAE 0.180 0.153 755 
 
MSE 0.056 0.097 
  
RMSE 0.236 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 585 77.48 
  
Individuals with MAE < 0.1 263 34.83 
  
Individuals with MAE < 0.05 137 18.15 
  
     
     
     
     
OLS Model A: Regressing SF-6D vs FSS total   
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  -0.006 0.000 -18.91 <0.0001 
       _cons  0.897 0.015 59.44 <0.0001 
R2 0.4511 
   
RMSE 0.09985 
   
Coefficients 1 
   
Sig coefficients 1 
   
 
Mean Std.Dev. Obs 
 
MAE 0.078 0.062 455 
 
MSE 0.010 0.015 
  
RMSE 0.100 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 449 98.68 
  
Individuals with MAE < 0.1 310 68.13 
  
Individuals with MAE < 0.05 188 41.32 
  
     
OLS Model B: Regressing SF-6D vs FSS total and FSS total squared 
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  -0.007 0.002 -4.31 <0.0001 
 FSS_squared  0.000 0.000 0.91 0.364 
       _cons  0.921 0.032 28.91 <0.0001 
R2 0.4521 
   
RMSE 0.09987 
   
Coefficients 2 
   
Sig coefficients 1 
   
 
Mean Std.Dev. Obs 
 
MAE 0.077 0.063 455 
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MSE 0.010 0.015 
  
RMSE 0.100 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 449 98.68 
  
Individuals with MAE < 0.1 312 68.57 
  
Individuals with MAE < 0.05 193 42.42 
  
     
OLS Model C: Regressing SF-6D vs FSS, age, gender 
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  -0.006 0.000 -19.07 <0.0001 
         age  -0.001 0.000 -2.64 0.009 
     female   -0.026 0.010 -2.5 0.013 
       _cons  0.970 0.026 37.29 <0.0001 
R2 0.4668 
   
RMSE 0.09888 
   
Coefficients 3 
   
Sig coefficients 3 
   
 
Mean Std.Dev. Obs 
 
MAE 0.078 0.060 452 
 
MSE 0.010 0.014 
  
RMSE 0.098 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 445 98.45 
  
Individuals with MAE < 0.1 309 68.36 
  
Individuals with MAE < 0.05 181 40.04 
  
     
OLS Model D: Regressing SF-6D vs FSS item scores 
EQ-5D Coefficient SE t P>|t| 
      FSS_01  -0.002 0.004 -0.55 0.580 
      FSS_02  -0.005 0.004 -1.38 0.168 
      FSS_03  -0.005 0.005 -0.99 0.323 
      FSS_04  0.001 0.005 0.22 0.830 
      FSS_05  -0.007 0.005 -1.5 0.135 
      FSS_06  -0.002 0.005 -0.5 0.618 
      FSS_07  -0.022 0.004 -4.94 <0.0001 
      FSS_08  0.008 0.004 2.14 0.033 
      FSS_09  -0.015 0.005 -3.06 0.002 
       _cons  0.871 0.018 49.25 <0.0001 
R2 0.4872 
   
RMSE 0.09738 
   
Coefficients 9 
   
Sig coefficients 3 
   
 
Mean Std.Dev. Obs 
 
MAE 0.075 0.061 455 
 
MSE 0.009 0.014 
  
RMSE 0.096 
   
 
Freq. Percent 
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Individuals with MAE < 0.25 448 98.46 
  
Individuals with MAE < 0.1 326 71.65 
  
Individuals with MAE < 0.05 193 42.42 
  
     
OLS Model E: Regressing SF-6D vs FSS item scores, age and gender  
EQ-5D Coefficient SE t P>|t| 
      FSS_01  -0.002 0.004 -0.48 0.630 
      FSS_02  -0.005 0.004 -1.46 0.145 
      FSS_03  -0.006 0.005 -1.07 0.283 
      FSS_04  0.001 0.005 0.13 0.898 
      FSS_05  -0.007 0.005 -1.43 0.153 
      FSS_06  -0.001 0.005 -0.25 0.805 
      FSS_07  -0.022 0.004 -5.04 <0.0001 
      FSS_08  0.009 0.004 2.33 0.020 
      FSS_09  -0.016 0.005 -3.43 0.001 
         age  -0.001 0.000 -2.39 0.017 
     female   -0.030 0.011 -2.81 0.005 
       _cons  0.943 0.029 32.57 <0.0001 
R2 0.5043 
   
RMSE 0.0962 
   
Coefficients 11 
   
Sig coefficients 5 
   
 
Mean Std.Dev. Obs 
 
MAE 0.074 0.059 452 
 
MSE 0.009 0.014 
  
RMSE 0.095 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 445 98.45 
  
Individuals with MAE < 0.1 326 72.12 
  
Individuals with MAE < 0.05 195 43.14 
  
     
     
     
OLS Model A: Regressing MSIS-8D vs FSS total   
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  -0.007 0.000 -17.29 <0.0001 
       _cons  0.961 0.016 58.69 <0.0001 
R2 0.3665 
   
RMSE 0.15046 
   
Coefficients 1 
   
Sig coefficients 1 
   
 
Mean Std.Dev. Obs 
 
MAE 0.119 0.092 493 
 
MSE 0.023 0.034 
  
RMSE 0.150 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 448 90.87 
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Individuals with MAE < 0.1 242 49.09 
  
Individuals with MAE < 0.05 136 27.59 
  
     
OLS Model B: Regressing MSIS-8D vs FSS total and FSS total squared 
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  0.003 0.002 1.67 0.096 
 FSS_squared  0.000 0.000 -5.08 <0.0001 
       _cons  0.785 0.033 23.82 <0.0001 
R2 0.3938 
   
RMSE 0.14734 
   
Coefficients 2 
   
Sig coefficients 1 
   
 
Mean Std.Dev. Obs 
 
MAE 0.116 0.090 493 
 
MSE 0.022 0.033 
  
RMSE 0.147 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 447 90.67 
  
Individuals with MAE < 0.1 257 52.13 
  
Individuals with MAE < 0.05 118 23.94 
  
     
OLS Model C: Regressing MSIS-8D vs FSS, age, gender 
EQ-5D Coefficient SE t P>|t| 
     FSS_tot  -0.007 0.000 -16.96 <0.0001 
         age  -0.001 0.001 -1.86 0.064 
     female   -0.008 0.016 -0.53 0.595 
       _cons  1.019 0.032 32.01 <0.0001 
R2 0.3718 
   
RMSE 0.15048 
   
Coefficients 3 
   
Sig coefficients 1 
   
 
Mean Std.Dev. Obs 
 
MAE 0.118 0.093 490 
 
MSE 0.022 0.034 
  
RMSE 0.150 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 447 91.22 
  
Individuals with MAE < 0.1 243 49.59 
  
Individuals with MAE < 0.05 133 27.14 
  
     
OLS Model D: Regressing MSIS-8D vs FSS item scores 
EQ-5D Coefficient SE t P>|t| 
      FSS_01  0.001 0.005 0.12 0.902 
      FSS_02  -0.005 0.005 -1.02 0.307 
      FSS_03  -0.009 0.006 -1.45 0.148 
      FSS_04  0.006 0.006 1.07 0.287 
      FSS_05  -0.024 0.007 -3.29 0.001 
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      FSS_06  -0.006 0.007 -0.81 0.417 
      FSS_07  -0.027 0.006 -4.5 <0.0001 
      FSS_08  0.025 0.004 5.81 <0.0001 
      FSS_09  -0.023 0.006 -3.82 <0.0001 
       _cons  0.902 0.020 44.71 <0.0001 
R2 0.4389 
   
RMSE 0.14277 
   
Coefficients 9 
   
Sig coefficients 4 
   
 
Mean Std.Dev. Obs 
 
MAE 0.109 0.089 493 
 
MSE 0.020 0.032 
  
RMSE 0.141 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 455 92.29 
  
Individuals with MAE < 0.1 265 53.75 
  
Individuals with MAE < 0.05 155 31.44 
  
     
OLS Model E: Regressing MSIS-8D vs FSS item scores, age and gender  
EQ-5D Coefficient SE t P>|t| 
      FSS_01  0.001 0.005 0.15 0.883 
      FSS_02  -0.005 0.005 -1.01 0.311 
      FSS_03  -0.009 0.006 -1.47 0.143 
      FSS_04  0.006 0.006 1.04 0.299 
      FSS_05  -0.024 0.007 -3.33 0.001 
      FSS_06  -0.005 0.007 -0.65 0.515 
      FSS_07  -0.027 0.006 -4.51 <0.0001 
      FSS_08  0.024 0.004 5.74 <0.0001 
      FSS_09  -0.023 0.006 -3.94 <0.0001 
         age  -0.001 0.001 -1.22 0.222 
     female   -0.014 0.016 -0.87 0.387 
       _cons  0.946 0.034 27.57 <0.0001 
R2 0.4419 
   
RMSE 0.14301 
   
Coefficients 11 
   
Sig coefficients 4 
   
 
Mean Std.Dev. Obs 
 
MAE 0.109 0.090 490 
 
MSE 0.020 0.033 
  
RMSE 0.141 
   
 
Freq. Percent 
  
Individuals with MAE < 0.25 455 92.86 
  
Individuals with MAE < 0.1 261 53.27 
  
Individuals with MAE < 0.05 157 32.04 
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Note that FSS-08 (fatigue is among my most disabling symptoms) has a positive coefficient 
FSS-01 (my motivation is lower when I am fatigued) has a positive coefficient in the EQ-5D and 
MSIS-8D models, but not in the SF-6D models 
 
Models run using estimation dataset, included significant FSS items only 
EQ-5D MODELS 
      
       
*CLAD Model C2 
            
Variable Observed Bias Std.Err. LCL UCL 
 
FSS total score -0.00576 -9.1E-05 0.000608 -0.00696 -0.00455 
 
Age -0.00309 -4.2E-05 0.000718 -0.00451 -0.00166 
 
Constant 1.084261 0.004113 0.049776 0.985494 1.183028 
 
Observations 755 
     
 
Mean Std.Dev. 
    
MAE 0.173114 0.183672 
    
MSE 0.063659 0.127679 
    
RMSE 0.252 
     
Pseudo R2 0.126022 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 597 79.07 
    
Individuals with MAE < 0.10 353 46.75 
    
Individuals with MAE < 0.05 190 25.17 
    
       
       
*CLAD Model D2 
            
Variable Observed Bias Std.Err. LCL UCL 
 
FSS_06 -0.026 0.002269 0.004559 -0.03505 -0.01695 
 
FSS_07 -0.02067 -0.00229 0.005582 -0.03174 -0.00959 
 
Constant 0.894667 -0.00099 0.016949 0.861036 0.928298 
 
Observations 774 
     
 
Mean Std.Dev. 
    
MAE 0.172271 0.186334 
    
MSE 0.064353 0.131224 
    
RMSE 0.254 
     
Pseudo R2 0.121661 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 608 78.55 
    
Individuals with MAE < 0.10 371 47.93 
    
Individuals with MAE < 0.05 221 28.55 
    
       
       
*CLAD Model E2 
            
Variable Observed Bias Std.Err. LCL UCL 
 
FSS_07 -0.02939 0.001426 0.00573 -0.04076 -0.01802 
 
FSS_09 -0.01681 -0.00099 0.004567 -0.02588 -0.00775 
 
Age -0.00302 1.63E-05 0.000681 -0.00437 -0.00167 
 
Constant 1.038418 -0.00442 0.048066 0.943045 1.133792 
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Observations 765 
     
 
Mean Std.Dev. 
    
MAE 0.171062 0.189995 
    
MSE 0.065313 0.134326 
    
RMSE 0.255565 
     
Pseudo R2 0.134896 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 607 79.35 
    
Individuals with MAE < 0.10 371 47.93 
    
Individuals with MAE < 0.05 222 29.02 
    
       
       
SF-6D MODELS 
      
       
*OLS Model D2 
            
SF_6Dv2 Coef. Std.Err. t P>|t| LCL UCL 
FSS_07 -0.02902 0.003348 -8.67 <0.0001 -0.0356 -0.02244 
FSS_09 -0.01699 0.00333 -5.1 <0.0001 -0.02353 -0.01045 
Constant 0.852329 0.012796 66.61 <0.0001 0.827182 0.877476 
Observations 460 
     
 
Mean Std.Dev. 
    
MAE 0.076699 0.061377 
    
MSE 0.009642 0.01459 
    
RMSE 0.098192 
     
R2 0.4639 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 454 98.7 
    
Individuals with MAE < 0.10 323 70.22 
    
Individuals with MAE < 0.05 193 41.96 
    
F-stat 180.27 
     
Prob 0 
     
       
*OLS Model E2 
            
SF_6Dv2 Coef. Std.Err. t P>|t| LCL UCL 
FSS_07 -0.02864 0.003345 -8.56 <0.0001 -0.03521 -0.02206 
FSS_09 -0.01747 0.003259 -5.36 <0.0001 -0.02387 -0.01106 
Age -0.00095 0.000418 -2.28 0.023 -0.00177 -0.00013 
Gender (female) -0.02583 0.010477 -2.47 0.014 -0.04642 -0.00524 
Constant 0.919073 0.024879 36.94 <0.0001 0.87018 0.967966 
Observations 457 
     
 
Mean Std.Dev. 
    
MAE 0.076046 0.060262 
    
MSE 0.009406 0.013951 
    
RMSE 0.096987 
     
R2 0.4796 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 448 98.03 
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Individuals with MAE < 0.10 318 69.58 
    
Individuals with MAE < 0.05 184 40.26 
    
F-stat 98.23 
     
Prob 0 
     
       
*CLAD Model D2 
            
Variable Observed Bias Std.Err. LCL UCL 
 
FSS_07 -0.03 -0.00061 0.004572 -0.03907 -0.02093 
 
FSS_09 -0.018 0.000174 0.004707 -0.02734 -0.00866 
 
Constant 0.858 0.003514 0.018524 0.821245 0.894755 
 
Observations 460 
     
 
Mean Std.Dev. 
    
MAE 0.076571 0.061931 
    
MSE 0.00969 0.01486 
    
RMSE 0.098 
     
Pseudo R2 0.275523 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 452 98.26 
    
Individuals with MAE < 0.10 325 70.65 
    
Individuals with MAE < 0.05 190 41.3 
    
       
       
*CLAD Model E2 
            
Variable Observed Bias Std.Err. LCL UCL 
 
FSS_07 -0.03085 0.000214 0.004454 -0.03969 -0.02201 
 
FSS_09 -0.0179 -0.00062 0.004468 -0.02677 -0.00903 
 
Gender (female) -0.0215 -0.00175 0.013233 -0.04776 0.004757  
Constant 0.90175 0.004941 0.031155 0.839932 0.963568 
 
Observations 460 
     
 
Mean Std.Dev. 
    
MAE 0.076436 0.061926 
    
MSE 0.009669 0.014696 
    
RMSE 0.09833 
     
Pseudo R2 0.279408 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 453 98.48 
    
Individuals with MAE < 0.10 324 70.43 
    
Individuals with MAE < 0.05 201 43.7 
    
       
       
MSIS-8D MODELS 
      
       
*OLS Model D2 
            
MSIS_8D Coef. Std.Err. t P>|t| LCL UCL 
FSS_05 -0.02755 0.005173 -5.33 <0.0001 -0.03771 -0.01738 
FSS_07 -0.03342 0.00496 -6.74 <0.0001 -0.04317 -0.02368 
Constant 0.914556 0.012816 71.36 <0.0001 0.889375 0.939736 
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Observations 500 
     
 
Mean Std.Dev. 
    
MAE 0.113603 0.090267 
    
MSE 0.021038 0.032955 
    
RMSE 0.145043 
     
R2 0.4048 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 459 91.8 
    
Individuals with MAE < 0.10 262 52.4 
    
Individuals with MAE < 0.05 138 27.6 
    
F-stat 170.87 
     
Prob 0 
     
       
*CLAD Model D2 
            
Variable Observed Bias Std.Err. LCL UCL 
 
FSS_07 -0.05296 -0.00163 0.003466 -0.05983 -0.04608 
 
Constant 0.908928 0.00911 0.013695 0.881754 0.936102 
 
Observations 501 
     
 
Mean Std.Dev. 
    
MAE 0.114843 0.102382 
    
MSE 0.02365 0.040465 
    
RMSE 0.154 
     
Pseudo R2 0.223803 
     
 
Freq. Percent 
    
Individuals with MAE < 0.25 449 89.62 
    
Individuals with MAE < 0.10 271 54.09 
    
Individuals with MAE < 0.05 154 30.74 
    
       
       
CLAD MODELS WITH P 
VALUES 
      
       
CLAD_eq_C2.smcl 
      
 
Coef. Std. Err z P>|z| LCL UCL 
FSS_tot -0.00576 0.000608 -9.47 <0.0001 -0.00695 -0.00456 
age -0.00309 0.000718 -4.3 <0.0001 -0.00449 -0.00168 
const 1.084261 0.049776 21.78 <0.0001 0.986701 1.181821 
       
       
CLAD_eq_D2.smcl 
      
 
Coef. Std. Err z P>|z| LCL UCL 
FSS_06 -0.026 0.004559 -5.7 <0.0001 -0.03493 -0.01707 
FSS_07 -0.02067 0.005582 -3.7 <0.0001 -0.03161 -0.00973 
const 0.894667 0.016949 52.79 <0.0001 0.861447 0.927886 
       
       
CLAD_eq_E2.smcl 
      
 
Coef. Std. Err z P>|z| LCL UCL 
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FSS_07 -0.02939 0.00573 -5.13 <0.0001 -0.04062 -0.01816 
FSS_09 -0.01681 0.004567 -3.68 <0.0001 -0.02577 -0.00786 
age -0.00302 0.000681 -4.43 <0.0001 -0.00435 -0.00168 
const 1.038418 0.048066 21.6 <0.0001 0.94421 1.132626 
       
       
CLAD_sf_D2.smcl 
      
 
Coef. Std. Err z P>|z| LCL UCL 
FSS_07 -0.03 0.004572 -6.56 <0.0001 -0.03896 -0.02104 
FSS_09 -0.018 0.004707 -3.82 <0.0001 -0.02723 -0.00878 
const 0.858 0.018524 46.32 <0.0001 0.821694 0.894306 
       
       
CLAD_sf_E2.smcl 
      
 
Coef. Std. Err z P>|z| LCL UCL 
FSS_07 -0.03085 0.004454 -6.93 <0.0001 -0.03958 -0.02212 
FSS_09 -0.0179 0.004468 -4.01 <0.0001 -0.02666 -0.00914 
Gender -0.0215 0.013233 -1.62 0.104 -0.04744 0.004436 
const 0.90175 0.031155 28.94 <0.0001 0.840688 0.962812 
       
       
CLAD_ms_D2.smcl 
      
 
Coef. Std. Err z P>|z| LCL UCL 
FSS_07 -0.05296 0.003466 -15.28 <0.0001 -0.05975 -0.04616 
const 0.908928 0.013695 66.37 <0.0001 0.882086 0.93577 
 
All models run using validation dataset 
EQ-5D CLAD MODEL 
A 
       
Variable Observed Bias SE LCL UCL z P>|z| 
FSS total score -0.00726 -0.00018 0.001184 -0.00966 -0.00528 -6.14 <0.0001 
Constant 1.001 0.005987 0.054856 0.9133 1.0968 18.25 <0.0001 
Observations 260 
      
 
Mean SD 
     
MAE 0.183491 0.206009 
     
MSE 0.075946 0.165228 
     
RMSE 0.276 
      
Pseudo R2 0.119159 
      
 
Freq. Percent 
     
Individuals with 
MAE<0.25 
205 78.85 
     
Individuals with 
MAE<0.10 
129 49.62 
     
Individuals with 
MAE<0.05 
64 24.62 
     
        
        
EQ-5D CLAD MODEL 
C 
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Variable Observed Bias SE LCL UCL z P>|z| 
FSS total score -0.00757 0.000273 0.001066 -0.01062 -0.00559 -7.1 <0.0001 
Age -0.00423 0.000525 0.001077 -0.0056 -0.00245 -3.92 <0.0001 
Gender (female) -0.00898 0.017491 0.025959 -0.04416 0.033484 -0.35 0.729 
Constant 1.233316 -0.06679 0.09793 1.094404 1.353203 12.59 <0.0001 
Observations 260 
      
 
Mean SD 
     
MAE 0.178599 0.198645 
     
MSE 0.071206 0.153685 
     
RMSE 0.267 
      
Pseudo R2 0.141096 
      
 
Freq. Percent 
     
Individuals with 
MAE<0.25 
200 76.92 
     
Individuals with 
MAE<0.10 
123 47.31 
     
Individuals with 
MAE<0.05 
67 25.77 
     
        
        
SF-6D OLS MODEL A 
       
SF_6Dv2 Coef. SE t P>t LCL UCL 
 
FSS total score -0.00401 0.000542 -7.4 0 -0.00508 -0.00294 
 
Constant 0.809539 0.026061 31.06 0 0.758044 0.861033 
 
Observations 152 
      
 
Mean SD 
     
MAE 0.068365 0.058008 
     
MSE 0.008017 0.012791 
     
RMSE 0.089535 
      
R2 0.3155 
      
 
Freq. Percent 
     
Individuals with 
MAE<0.25 
150 98.68 
     
Individuals with 
MAE<0.10 
116 76.32 
     
Individuals with 
MAE<0.05 
74 48.68 
     
F 54.71 
      
Prob 0 
      
        
        
SF-6D CLAD MODEL A 
       
Variable Observed Bias SE LCL UCL z P>|z| 
FSS total score -0.00377 -0.00017 0.000729 -0.00519 -0.002 -5.18 <0.0001 
Constant 0.792955 0.009771 0.039386 0.738167 0.886 20.13 <0.0001 
Observations 152 
      
 
Mean SD 
     
MAE 0.068255 0.059064 
     
MSE 0.008124 0.012945 
     
RMSE 0.09 
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Pseudo R2 0.168562 
      
 
Freq. Percent 
     
Individuals with 
MAE<0.25 
149 98.03 
     
Individuals with 
MAE<0.10 
114 75 
     
Individuals with 
MAE<0.05 
70 46.05 
     
        
        
SF-6D CLAD MODEL C 
       
Variable Observed Bias SE LCL UCL z P>|z| 
FSS total score -0.0041 0.000174 0.000789 -0.00546 -0.00302 -5.19 <0.0001 
Age -0.00043 7.25E-05 0.000917 -0.00195 0.001836 -0.47 0.636 
Gender (female) 0.00184 -0.00312 0.018711 -0.03795 0.035211 0.1 0.922 
Constant 0.826868 -0.0029 0.078108 0.676031 0.992854 10.59 <0.0001 
Observations 152 
      
 
Mean SD 
     
MAE 0.070781 0.063761 
     
MSE 0.009049 0.014786 
     
RMSE 0.095 
      
Pseudo R2 0.169288 
      
 
Freq. Percent 
     
Individuals with 
MAE<0.25 
149 98.03 
     
Individuals with 
MAE<0.10 
115 75.66 
     
Individuals with 
MAE<0.05 
70 46.05 
     
        
        
MSIS-8D CLAD 
MODEL A 
       
Variable Observed Bias SE LCL UCL z P>|z| 
FSS total score -0.00639 -2.8E-06 0.000966 -0.01004 -0.00519 -6.61 <0.0001 
Constant 0.939022 0.005128 0.043165 0.903513 1.131484 21.75 <0.0001 
Observations 157 
      
 
Mean SD 
     
MAE 0.118181 0.094082 
     
MSE 0.022762 0.044508 
     
RMSE 0.151 
      
Pseudo R2 0.180284 
      
 
Freq. Percent 
     
Individuals with 
MAE<0.25 
145 92.36 
     
Individuals with 
MAE<0.10 
79 50.32 
     
Individuals with 
MAE<0.05 
36 22.93 
     
        
        
MSIS-8D CLAD 
MODEL C 
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Variable Observed Bias SE LCL UCL z P>|z| 
FSS total score -0.00597 -0.00019 0.001074 -0.00897 -0.00435 -5.56 <0.0001 
Age -0.00149 0.000546 0.002014 -0.00385 0.002588 -0.74 0.459 
Gender (female) 0.011789 0.01073 0.039513 -0.0528 0.08738 0.3 0.765 
Constant 0.974376 -0.02785 0.125225 0.728175 1.13045 7.78 <0.0001 
Observations 157 
      
 
Mean SD 
     
MAE 0.114289 0.096382 
     
MSE 0.022292 0.035955 
     
RMSE 0.149 
      
Pseudo R2 0.185381 
      
 
Freq. Percent 
     
Individuals with 
MAE<0.25 
143 91.08 
     
Individuals with 
MAE<0.10 
82 52.23 
     
Individuals with 
MAE<0.05 
49 31.21 
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Additional file 5 
 
Scatterplots of observed vs predicted HSVs 
               
Observed EQ-5D vs EQ-5D estimated using CLAD A            Observed EQ-5D vs EQ-5D estimated using CLAD C 
 
               
Observed MSIS-8D vs MSIS-8D estimated using CLAD A            Observed MSIS-8D vs MSIS-8D estimated using CLAD C 
 
Observed SF-6D vs SF-6D estimated using OLS A  
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Additional file 6: Observed versus predicted HSVs 
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